Thomas Schürpf

Company: Parthenon Therapeutics

Job title: Senior Director, Tumor Biology

Seminars:

Breaking Down Barriers In Immune-Excluded Tumor Biology 3:45 pm

Immune exclusion in tumors has been associated with unfavorable clinical outcome and poor response to therapy Therapies targeting immune exclusion are orthogonal to cancer immunotherapy and could improve responses DDR1 as an example of a druggable target implicated in establishing mechanical barriers for an immune responseRead more

day: Day Two